you, Thank Andre.
First, I'll on disease our Parkinson's recent through go updates program.
which Steady We've of the more are before detailed As to be the entered this year with RESTORE-X from FDA made for is good a RESTORE-X continues the earlier to provide off and Neurocrine progress proposed agreed receive requesting RESTORE-X we a statistical Andre collaboration start. mentioned, analysis enrollment the We'll toward year-end. trial. to update we after agency. from feedback feedback on plan
of differentiated. our of consists function. a of therapy with where small program Parkinson's the volume the of for As disease reminder, VY-AADC a is to it needed targeted to It delivery approach the the is region gene motor brain highly
levodopa transient a ability to a is to gene will This dying then is dopamine will a work used delivered own, combination result unique controllable but care neurons By healthy bypassing introducing the AADC and regulate neurons we're with therapy. AADC the highly nothing convert its the putamen levodopa dopamine. for system the do activity putamen, post-synaptic be desirable AADC, pre-synaptic needed and dopamine. into produce regulatable AAV produce creating in in feature the reservoir to rather into by oral enzyme medication. to The of standard on and AADC of an
degenerative in to results starting a the the may over and of effect avoid the of longer-term initiated now impacts progression. of contrast of negative the Xb to both ability exogenous of the manage XXXX, dopamine that trial much and was in too the not spoke, is speak needed. Phase needed the regions to predicted disease Our in disease it course their to progressive control context against gives the approach so see where dopamine patient amount brain we're motor durability function
from scientific We months from XXXX. two-year in at as expect PD-XXXX, XX cohorts, present to all data meetings data three as well PD-XXXX
completing in BLA to will time are five data of This us provide enrolling years our PD-XXXX eventually Patients the now in discussions. PD-XXXX with study. on extension at data payer addition over filing and the three-year and longer-term placebo-controlled the protocol of
clinical as neurologists design program Our and neurosurgeons as also proposed trial have both disease biomarker progressing positive our with our advisory held assessments. We've on meetings approach, Huntington's feedback is delivery received and well. and well
delivery learnings putamen. into the with our Parkinson's leverages VY-HTTXX of approach delivery Our from local program the
we're and delivering of thalamus. disease, to into changes earliest noticeable directly the vector our striatum cortex the cortex. the delivery are to this Huntington's also becoming the approach importance as Huntington's on in delivering based changes evident as the the in the We chose as disease of striatum the progresses. Pathological well understanding of with For disease pathology disease
In fact, in brain Huntington's the patient certain with deteriorating the of disease before areas appeared. that well the are symptoms
to our rich leverage preserved between connections putamen to thalamus, as striatum, enough The in our the impact as HTT Gene reach cortex is Therapy and to oral presented the the to meeting thalamus Huntington's program and should brain. well vector in largely European stages to We early update the on in thalamus in a Last the of presentation. at as therapy platform deliver outer previously we Delivery well disease. knockdown of the an data the the during contrast as us of as allow of an VY-HTTXX month gene primates. the presented well non-human bio-distribution, mRNA the on Society effect Barcelona, of as brains structure dose-dependent Cell
are further putamen efficacious. mRNA in the provide lowering In huntingtin to is our evidence in thalamus in results HTT huntingtin regions that evidence reductions findings significant NHP protein distribution recent huntingtin levels predicted and the presentation, we analyzed. that and in with lowers provided be gene reduction protein These delivered efficiently clinically therapy the that brain vector mRNA and genome and protein VY-HTTXX commensurate new that our to also to
We VY-HTTXX half now Huntington's expect for filing disease first an during of IND for the XXXX.
interim final of with on huntingtin non-human data one-year the submitting application pre-clinical instead months different six primates kinetics our be rodents. We As to an knock-down of studies IND previously plan data. appeared planned in than the in from
to between and Our the IND is goal dosed. of amount minimize time first acceptance patient
toward engagement to this. already place the and have We related to our selection will take leveraging Parkinson's will disease the site experience in be beginning quarter of in continue clinical XXXX. fourth begun and achieve Activities
during of expect the We patient first XXXX. study continue to and clinical dosing screening and
pipeline the programs vectorized ataxia Friedreich's program including with our antibody other AbbVie to two Neurocrine with and progress. continue programs Our
for support the schedule on to on plans AbbVie working are ataxia our and of work on lead studies candidate continue selection deliver collaborations. against or Friedreich's ahead We to
the in targets compelling disease, pursuing and therapy. own gene several agreed working our for against targets are With that new opportunities we've are targets. with discovery neurological Additionally, discovery efforts AAV we're our expertise and two on Neurocrine on focus
XXXX. provide to new information expect more on during programs We
I'll to the Vasilis on call now for pass the financial update.
